

Building the Future of International Urology

education / research / publications / networking / philanthropy



For Healthcare Professionals only.

Helping him focus on the moments that matter

DUODART* (dutasteride/tamsulosin) and **AVODART*** (dutasteride) have long been used by HCPs across the globe to help **men with moderate to severe LUTS due to BPH†** be present for those big moments.*¹⁻⁶

The UK trade name for dutasteride/tamsulosin is **Combodart**.



DUODART and AVODART are supported by landmark trials of 5-ARIs in 11,868 patients, including 6909 patients who received dutasteride as monotherapy and in combination with tamsulosin.^{§7-12}

Both dutasteride-containing treatments are available in a **90s pack** for long-term treatment as recommended by guidelines.^{||1,2,13}

DUODART
(dutasteride/tamsulosin HCl) Capsules

Used by HCPs
for over a decade.³
Registered in 85
countries worldwide.⁴

Avodart
dutasteride

Used by HCPs for
over two decades.⁵
Registered in 95
countries worldwide.⁶

**Consider DUODART or AVODART[®] as a first choice
for your patients with moderate to severe BPH^{1,2,7-12}**



Click or scan this QR code to
view prescribing information
for **Duodart**



Click or scan this QR code to
view prescribing information
for **Avodart**

Adverse events associated with **Duodart** and **Avodart** include impotence, decreased libido, ejaculation disorders, breast tenderness and enlargement, and dizziness.^{2,13}

*In some countries, Duodart may be registered under other trade names, e.g. Combodart, Doubluts, Jalyn, Duagen, dutasteride-tamsulosin GSK, Jelnu or Juteo.⁴ †In some countries, Avodart may be registered under other trade names, such as Avolve, Duagen, Zygard, Avidart or Dutasteride GlaxoSmithKline.⁶ §Men with moderate to severe LUTS/BPH at risk of disease progression.^{1,2} §The overall number of patients studied in landmark trials of 5-ARIs is 11,868 with Phase III: 4325; EPICS: 1630; SMART: 327; CombAT: 4844; CONDUCT: 742. The number of patients studied in landmark trials with dutasteride as monotherapy or in combination with tamsulosin is 6,909 with Phase III: 2167; EPICS: 813; SMART: 327; CombAT: 3233; CONDUCT: 369.⁷⁻¹² ¶90s pack not available in all countries. ¶In combination with an α 1-blocker.¹

Licensed indication for Duodart & Avodart: Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH). Reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.^{2,13}

Abbreviations

5-ARI, 5-alpha reductase inhibitor; AUR, acute urinary retention; BPH, benign prostatic hyperplasia; HCP, healthcare professional; LUTS, lower urinary tract symptoms; UK, United Kingdom.

References

1. Cornu JN, et al. EAU guidelines on the treatment of non-neurogenic male lower urinary tract symptoms (LUTS). 2025. Available at: <https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts>. Accessed September 2025. 2. Duodart EU Summary of Product Characteristics effective 23 November 2017. Available at: <https://mri.cts-mrp.eu/portal/details?productnumber=DE%2FH%2F2251%2F001>. Accessed September 2025. 3. GSK Data on File Duodart first received approval in 2010; August 2024. Document Number REF-244686. 4. GSK Data on File 2022N516537_00; 1-2; August 2024. Document number REF-244486. 5. GSK Data on File Avodart received approval in 2001; August 2024. Document Number REF-244689. 6. GSK Data on File 2022N516400_00; 1-2; August 2024. Document number REF-244484. 7. Roehrborn CG, et al. *BJU Int* 2015;116:450-459. 8. Roehrborn CG, et al. *Eur Urol* 2010;57:123-131. 9. Roehrborn CG, et al. *Urology* 2002;60:434-441. 10. Barkin J, et al. *Eur Urol* 2003;44:461-466. 11. Debruyne F, et al. *Eur Urol* 2004;46:488-494. 12. Nickel JC, et al. *BJU Int* 2011;108:388-394. 13. Avodart EU Summary of Product Characteristics effective 23 November 2017. Available at: <https://mri.cts-mrp.eu/portal/details?productnumber=SE%2FH%2F0304%2F001>. Accessed September 2025.

Adverse events should be reported. For UK, reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellowcard in the Google Play or Apple App Store. Outside of the UK, adverse events should be reported as country regulations dictate. Adverse events should also be reported to GSK on 0800 221 441. For contact details and to report a possible side effect outside of the UK please access the following link <https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect>

Avodart/Combodart/Duodart is for use in men only. Avodart/Combodart/Duodart trade marks are owned by or licensed to the GSK group of companies. Please refer to your local Summary of Product Characteristics (SmPC) before prescribing. For the use of registered medical practitioner, Hospital or Laboratory only. This material was developed in compliance with the ABPI and EFPIA codes. Avodart/Combodart/Duodart may not be marketed/authorised in all countries.



CONTENTS

UMAG

MAGAZINE

The Magazine of the Société
Internationale d'Urologie

2025 Photos: SIU Image Bank.
All information published is
accurate as of time of print.



SIU Central Office

1134 Ste-Catherine Street West
Suite 920 Montreal (Quebec)
Canada H3B 1H4
Tel: +1 (514) 875-5665
Fax: +1 (514) 875-0205
communications@siu-urology.org
siu-urology.org #SIUWorld



© 2025 Société Internationale d'Urologie

3

SIU Governance

Message from the President

2024-2025 SIU Board of Directors

4

SIU Membership

Make Your Mark on Global Urology

6

SIU 2025 Congress

Surgery Day Programme

Special Congress Event:
7th Bench-to-Bedside
Uro-Oncology: GU Cancers Triad

15

SIU Office of Education

Governance

Latest Content in the
SIU Academy Collection

Best of 2024: Top 5 Sessions

ICUD Publications: New and
Upcoming!

Call for Endorsed Events

20

SIUJ

Editorial Board

SIUJ: On the Horizon—Indexing

Accessing the Journal

Journal Awards

23

uCARE

Governance

Join uCARE's BPH Global Registry

24

SIU Institutes and Scholarships

Scholarships

SIU Scholar Snapshots

SIU Training Centres

29

Sponsor Acknowledgements

TECHNOLOGICAL INNOVATIONS

for Detection and Treatment of NMIBC

SS-01: THURSDAY, OCTOBER 30

12:45–14:00 GMT

Fintry Auditorium, L3, EICC

Chair



Bernard Malavaud, MD, PhD, FEBU

Urology Department, Institut Universitaire du Cancer
Toulouse-Oncopole, Toulouse, France

Speakers



Gigja Gudbrandsdottir, MD, PhD
Haukeland University Hospital,
Bergen, Norway



Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)
Faculty of Medicine, The Chinese University of
Hong Kong, Hong Kong



Juan Luis Vásquez, MD, PhD
Department of Urology, Copenhagen
University Hospital - Zealand University
Hospital Roskilde, Roskilde, Denmark

This session will be transmitted live via the SIU Congress platform. SIU @U



Dear Friends,

E pluribus unum
"Out of many, one"

My journey with the SIU has taken me on many different adventures over the years: from participating as an invited speaker and attending SIU Congresses around the world, to becoming a member and learning about the many offerings of the Society, to finally joining the Board of Directors and developing new and enriching initiatives and activities. Over this time, I have witnessed the extraordinary accomplishments that can come from many working as one.

It is my honour to now serve as President of the Society and shepherd the SIU into a new era that will certainly bring further growth and greater success. The active participation of every member is integral to the advancement of our mission. Together, we build on the strong foundation laid by those before us and continue to foster collaboration, innovation, and education that will shape the future of urology worldwide.

In a world where it is easy to focus only on what is at your front door, I invite you to take a step onto the international stage and join this vibrant and dedicated community to work as one in advancing urological care for patients all around the world.

Jean de la Rosette, *SIU President, Türkiye*

2024–2025 SIU BOARD OF DIRECTORS

Jean de la Rosette, Türkiye
President

William Lynch, Australia
President Elect

Yasser Farahat, United Arab Emirates
Vice President

Rajeev Kumar, India
Past President and Nominating Committee Chair

Stavros Gravas, Cyprus
General Secretary

Rafael Sanchez-Salas, Canada
Treasurer

Mauro Gacci, Italy
Office of Education

Mihir Desai, United States
Office of Research

Vincenzo Ficarra, Italy
Publications

Jeremy Teoh, Hong Kong
Congress Organizing

Hiroji Uemura, Japan
Corporate Development

Membership and International Relations
Papa Ahmed Fall, Senegal
Africa and Middle East

Juan Carlos Castaño, Colombia
Americas

Madhu Agrawal, India
Asia-Pacific

Franck Bladou, France
Europe

Philippe Spiess, United States
Consensus and Education

Dean Elterman, Canada
Innovators

Junhua Zheng, China
Institutes and Scholarships

Rajeev T P, India
Scientific Programme Co-Chair

Seth Lerner, United States
Scientific Programme Co-Chair

Ranan Dasgupta, United Kingdom
Research Committee

Sung Kyu Hong, South Korea
Uro Technology Training

Rajeev Sood, India
National Society Delegate Representative

Francisco J. Sanchez G., Mexico
National Society Delegate Representative

Paksi Satyagraha, Indonesia
General Assembly Representative

Gonzalo Vitagliano, Argentina
General Assembly Representative

SIU MEMBERSHIP

MAKE YOUR MARK ON **GLOBAL UROLOGY**

Join the SIU today and see how your membership:



LEVELS THE PLAYING FIELD

Dues **subsidize membership fees and Congress registrations and fund scholarship programmes** for urologists from middle- and low-income countries.



STEERS THE FUTURE OF THE SIU

Members are encouraged to **nominate new Board members**.



MAKES EDUCATION ACCESSIBLE

There is no charge to **publish in or to read SIUJ**, and **SIU Academy** is a user-friendly eLearning platform with a **rich library of free content**.



ADVANCES RESEARCH

Institutions are still being enrolled in the latest **uCARE registry**.



BUILDS COMMUNITY

Valuable **connections** are made amongst members. Spread the word and invite colleagues to join.

In recognition of their contributions to the Society, members enjoy

- Access to SIU Academy and SIUJ
- Reduced Congress fees
- Global networking opportunities
- Educational events, online and in-person

Residents and trainees are eligible for free membership.



APPLY TODAY
siu-urology.org/society/join-siu

PSMA PET Imaging and Radioligand Therapy in Prostate Cancer

What Urologists Need to Know in 2025

SS-02 • Thursday, October 30, 2025 • 1245-1400 GMT

Sidlaw Auditorium, L3, EICC

Discover the Role of PSMA PET Imaging and Radioligand Therapy in Advanced Prostate Cancer Management

Learning Objectives

At the end of this symposium, participants should be able to:

- Recall the fundamentals of PSMA imaging and radioligand therapy in the contemporary management of prostate cancer.
- Summarize the basics of PSMA PET/CT imaging acquisition, interpretation, and clinical indications as well as its role in guiding treatment decision-making in prostate cancer management.
- Outline the current PSMA-targeted radioligand therapies and supporting clinical evidence in the management of eligible patients with mCRPC.
- Recognize the role of a multidisciplinary tumour board in guiding the management of patients with advanced prostate cancer in clinical practice.

Chair



Robert Reiter, MD, MBA
Department of Urology, University
of California Los Angeles,
Los Angeles, United States

Speakers



**Amit Bahl, MBBS, MD, DNB, FRCP,
FRCR, FFRCSI**
Bristol Haematology and Oncology
Centre, University Hospitals Bristol,
Bristol, United Kingdom



Thomas Langbein, MD
Clinic for Nuclear
Medicine, Zentralklinik
Bad Berka, Bad Berka,
Germany

This session will be transmitted live via the SIU Congress platform. SIU @U

Novartis products will be discussed and prescribing information will be available at the meeting. For UK HCPs, please scan the QR codes to access the respective prescribing information.



Pluvicto▼ [lutetium (177Lu) vipivotide tetraxetan] is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.



Locametz▼ (gozetotide), after radiolabelling with gallium-68, is a radioactive diagnostic agent indicated for the identification of prostate-specific membrane antigen (PSMA)-positive lesions by positron emission tomography (PET) in adult patients with prostate cancer.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370.



45th Congress of the Société Internationale d'Urologie

Featuring the:
BENCH 2 BEDSIDE
URO-ONCOLOGY
GU CANCERS TRIAD MEETING
7th B2B Uro-Oncology:
GU Cancers Triad Meeting



SURGERY DAY Programme

October 30, 2025 **0730–1705 GMT** **Pentland, L3, EICC**



Surgery Day will be livestreamed on the *SIU@U* app, included with your Congress in-person and virtual registration.

About Surgery Day

This dynamic, all day session will highlight essential urological procedures in endourology of upper and lower urinary tract, uro-oncology and focal therapy, and reconstruction. Led by internationally renowned experts, the programme will feature real-time transmissions of live surgeries from prominent centres, alongside engaging semi-live presentations. Join us for insights into innovative technologies, advanced instrumentation, and cutting-edge techniques.

Surgery Day Co-Chairs



Stavros Gravas
Cyprus



Rajeev Kumar
India



Jean de la Rosette
Türkiye

Learning Objectives:

At the end of this session, attendees should be able to:

- Update knowledge of recent developments in equipment and technique for the minimally invasive and surgical management of urologic diseases, based on live and pre-recorded surgical demonstrations.
- Acknowledge the role of open, laparoscopic, and robotic-assisted surgical procedures in uro-oncology and reconstructive urology, with respect to new systems, instrumentation, and techniques.
- Summarize practical knowledge of instrumentation and techniques for the endourologic treatment of upper and lower urinary tract conditions.
- Recognize the role of focal therapy approaches in uro-oncology.
- Recall perioperative considerations for optimizing urologic surgery outcomes, based on treatment guidelines and expert opinion.

Watch this session live to claim **CME credits**.

This educational programme is supported by:

Corporate Sponsor: Procept BioRobotics

Congress Contributors: Coloplast, Edge Medical, Laborie, Medtronic, MicroPort, Pusen, Simai Co., Ltd., Sofmedica, Sonablate, Teleflex, YiGaoMed.



SURGERY DAY Programme

October 30, 2025 **0730–1705 GMT** **Pentland, L3, EICC**

Session 1: Endourology/Stones and Uro-Oncology

Co-Chairs: Sung Yong Cho (Korea), Stelios Giannakopoulos (Greece)

Faculty Panel: Sung Kyu Hong (Korea), Hegel Trujillo-Santamaria (Mexico), Kai Zhang (China)

Time GMT	Screen 1	Screen 2
0730-0800	LIVE Exclusive: Flexible and Navigable Suction Ureteral Access Sheath (FANS) With Pressure Monitor in RIRS Surgeon: Guohua Zeng (China)	
0800-0830	LIVE Exclusive: Robot-Assisted Partial Nephrectomy Surgeon: Xin Ma (China)	
0830-0845	SEMI-LIVE Exclusive: Direct-in-Scope-Suction (DISS) in Action: Improving Efficiency and Vision Surgeon: Bhaskar Somani (United Kingdom)	
0845-0900	SEMI-LIVE Shared: Supine PCNL Surgeon: Wojciech Krajewski (Poland)	SEMI-LIVE Shared: Prone PCNL Surgeon: Hiren Sodha (India)

Session 2: Endourology/Stones/LUTS/BPH, Uro-Oncology and Reconstruction

Co-Chairs: Madhu Agrawal (India), Hammad Ather (Pakistan)

Faculty Panel: Kamel Ait El Hadj (Algeria), Linat Kutliyarov (Russia), Yongwei Lim (Singapore), Merycarla Pichardo (Dominican Republic)

Time GMT	Screen 1	Time GMT	Screen 2
1115-1135	SEMI-LIVE Shared: Robotic Simple Prostatectomy for BPH Surgeon: Mihir Desai (United States)	1115-1200	LIVE Shared: Robotic Partial Nephrectomy Surgeon: Valentin Pavlov (Russia)
1140-1200	SEMI-LIVE Shared: Lower Pole Stone Surgeon: Amelia Pietropaolo (United Kingdom)		
1200-1220	SEMI-LIVE Shared: Bipolar Transurethral Enucleation of the Prostate for BPH Over 150 g With Median Lobe Protrusion Surgeon: Li-Ping Xie (China)	1200-1220	SEMI-LIVE Shared: Evidence-Based Progress in RIRS with DISS Technology Surgeon: Bogdan Geavlete (Romania)
1220-1235	SEMI-LIVE Exclusive: Robotic Kidney Transplantation Surgeon: Anant Kumar (India)		

Session 3: Uro-Oncology and Focal Therapy

Co-Chairs: Prokar Dasgupta (United Kingdom), Matin Sheriff (United Kingdom)

Faculty Panel: Grigorios Athanasiadis (United Kingdom), Leonard Gomella (United States), Badrinath Konety (United States)

Time GMT	Screen 1	Screen 2
1400-1445	LIVE Shared: Robotic Radical Prostatectomy with Telesurgery Surgeon: Geert De Naeyer (Belgium)	LIVE Shared: Clipless Robotic-Assisted Radical Prostatectomy Surgeon: Dmitry Pushkar (Russia)
1445-1530	LIVE Shared: Clipless Retzius-Sparing Robotic Prostatectomy Surgeon: Wissam Abou-Chedid (United Kingdom)	LIVE Shared: Robotic Partial Nephrectomy Surgeon: Rocco Papalia (Italy)
1530-1550	SEMI-LIVE Shared: Lateral Approach in Nerve-Sparing Robotic Radical Prostatectomy Surgeon: Markos Karavitakis (Greece)	SEMI-LIVE Shared: Focal Therapy With HIFU Surgeon: Alistair Grey (United Kingdom)

Session 4: Endourology/Stones/ LUTS/BPH and Reconstruction

Co-Chairs: Peter Gilling (New Zealand), Pilar Laguna (Türkiye)

Faculty Panel: Gökhan Çalık (Türkiye), Odunayo Kalejaiye (United Kingdom), Andreas Skolarikos (Greece)

Time GMT	Screen 1	Screen 2
1600-1615	SEMI-LIVE Exclusive: Mini-PCNL Using Thulium Fiber Laser Surgeon: Vitor Cavadas (Portugal)	
1615-1630	SEMI-LIVE Exclusive: Paclitaxel-Coated Balloon for the Treatment of Anterior Urethral Stricture Surgeon: Feras Al Jaafari (United Kingdom)	
1630-1645	SEMI-LIVE Exclusive: Aquablation for BPH Surgeon: Juan Justo Quintas (Spain)	
1645-1705	SEMI-LIVE Shared: Treating Obstructive Median Lobes With Prostatic Urethral Lift System Surgeon: Silvia Secco (Italy)	SEMI-LIVE Shared: Urethroplasty - Panurethral Stricture Surgeon: Evelyn Moshokoa (South Africa)

The 45th Congress of the Société Internationale d'Urologie has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®). Watch this session live and claim up to **6.0 ECMEC® credits**.

CONTRIBUTE TO THE ADVANCEMENT OF UROLOGY CARE WORLDWIDE!




Suction in Endourology:

More Than Just Suction,
Understanding Fluid Dynamics

SS-05: Thursday, October 30
10:45–11:15 GMT

Sidlaw Auditorium, L3, EICC



Chair



Steffi Kar Kei Yuen, MBBS, FRCSEd(Urol), FCSHK, FHKAM (Surgery)
S.H. Ho Urology Centre, Department of Surgery, The Chinese
University of Hong Kong, Hong Kong

Speakers



Vineet Gauhar, MD
Department of Urology, Ng Teng Fong
Hospital, Singapore, Singapore



Jia-Lun Kwok, MBBS, FRCS(Urol)(Glasg)
Department of Urology Tan Tock Seng
Hospital, Singapore, Singapore



Bhaskar Somani, MRCS,
FEBU, FRCS(Urol)
University Hospital Southampton
NHS Foundation Trust,
Southampton, United Kingdom

This session will be transmitted live via the SIU Congress platform. SIU @ U

This symposium is supported by SIU Congress Contributor ZSR.

#SIU2025Edinburgh #SIUatU



B2B Scientific Programme Committee



**BENCH OF
BEDSIDE**
URO-ONCOLOGY
GU CANCERS TRIAD

In conjunction with
SIU
Around the
WORLD
EDINBURGH 2025

Friday, October 31, 2025 1000–1730 GMT Room: Sidlaw, L3

ABOUT THE MEETING

Watch world-renowned experts present the latest advances in the management of the three most prevalent GU cancers: bladder, kidney, and prostate. Interact with the faculty and participate in dynamic discussions on the evolving management of GU cancers.



The B2B Meeting will be livestreamed on the *SIU@U* app, included with your Congress registration.

LEARNING OBJECTIVES

At the end of this programme, participants will be able to:

- Evaluate the benefits, risks, and limitations of various treatment options across the management continuum in prostate cancer, bladder cancer, and kidney cancer.
- Recognize the role of imaging and genetic markers in guiding treatment decision-making.
- Analyze the efficacy and safety of emerging therapeutic approaches for the management of GU cancers based on current clinical data.
- Recall strategies to identify, manage, and mitigate adverse events related to systemic treatment.
- Discuss the importance of personalized medicine, based on treatment costs and patient preference, while minimizing toxicity and maximizing efficacy.

Make Sure To Attend

**B2B Luncheon Symposium:
HER2-Targeted Antibody Drug Conjugates
in Metastatic Bladder Cancer:
A New Era of Precision Oncology**

Friday, October 31, 2025
1200–1245 GMT

**B2B Breakfast Symposium:
Innovative Technologies Transforming
Bladder Cancer Care**

Saturday, November 1, 2025
0800–0845 GMT

Watch this session live to claim **CME credits**.

The B2B Uro-Oncology: GU Cancers Triad Meeting is supported by:
Presenting Sponsors: Daiichi - Sankyo | AstraZeneca, Johnson & Johnson
Contributing Sponsors: Bristol Myers Squibb, CG Oncology,
Ferring Pharmaceuticals, Merck Sharp & Dohme LLC, Novartis

PROGRAMME AGENDA

Edinburgh International Conference Centre (EICC)
Edinburgh, Scotland
Friday, October 31, 2025



BENCH TO BEDSIDE
URO-ONCOLOGY
GU CANCERS TRIAD



TIME GMT	SESSION TITLE	SPEAKERS
1000–1005	Welcome and Introductions	Peter Black (Canada) / Simon Tanguay (Canada)
1005–1145	Bladder Cancer – Moderator: Peter Black	
1005–1030	Debate: Immune Checkpoint Blockade Plus BCG Is the New Standard First-Line Therapy for High-Risk NMIBC	Moderator: Peter Black Pro: Kilian Gust (Austria) Con: Param Mariappan (UK)
1030–1055	Debate: En Bloc Is Superior to Conventional TURBT for Initial Management of NMIBC	Moderator: Peter Black Pro: Jeremy Teoh (Hong Kong) Con: Stephen Williams (USA)
1055–1110	Advances in Perioperative Therapy for Muscle-Invasive Bladder Cancer	Karima Oualla (Morocco)
1110–1145	Panel discussion: Systemic Therapy in Metastatic Bladder Cancer	Moderator: Kilian Gust Panel: Robert Jones (UK), Karima Oualla, Daniele Raggi (UK)
1145–1200	Break	
1200–1245	B2B Luncheon Symposium	
	HER2-Targeted Antibody-Drug Conjugates in Metastatic Bladder Cancer: A New Era of Precision Oncology	Chair/Moderator: Karima Oualla Speakers: Kilian Gust, Daniele Raggi, Viktor Gruenwald (Germany)
1245–1425	Kidney Cancer – Moderator: Simon Tanguay	
1245–1300	IO Rechallenge After Adjuvant IO	Viktor Gruenwald
1300–1315	Cytoreductive Nephrectomy in the Era of IO	Arnaud Méjean (France)
1315–1340	Debate: Treatment of Oligometastatic RCC: When Is It Best to Use Surgery vs SBRT?	Moderator: Simon Tanguay Surgery: Axel Bex (UK) SBRT: Amy Clifford (UK)
1340–1410	Panel Discussion: Systemic Therapy Combination in Metastatic RCC	Moderator: Simon Tanguay Panel: Viktor Gruenwald, Christian Kollmannsberger (Canada), Karima Oualla
1410–1425	Belzutifan in Metastatic Clear Cell RCC	Christian Kollmannsberger
1425–1440	Break	
1440–1620	Prostate Cancer – Moderator: Caroline Moore	
1440–1510	Panel Discussion: Focal Therapy in Localized Prostate Cancer – Assessing Different Energy Sources	Moderator: Caroline Moore (UK) Panel: Hashim Ahmed (UK), Kara Watts (USA), Alistair Grey (UK), Rafael Sanchez-Salas (Canada)
1510–1550	Robotic Prostatectomy Balloon Debate: The Data on X Approach Is Sufficient for Widespread Implementation	Moderator: Rafael Sanchez-Salas Debaters: NeuroSAFE: Derya Tilki (Germany) Retzius sparing: Silvia Secco (Italy) Single port: John Davis (USA) Hood: Alan McNeill (UK)
1550–1605	Role of Metformin Plus ADT in mHSPC – a STAMPEDE Update	Nick James (UK)
1605–1620	Theranostics in Locally Advanced Prostate Cancer	Jan Philipp Radtke (Germany)
1620–1625	Break	
1625–1725	Five Practice-Changing Advances on the Horizon – Moderators: Peter Black / Simon Tanguay	
1625–1645	Bladder Cancer	Kilian Gust
1645–1705	Kidney Cancer	Axel Bex
1705–1725	Prostate Cancer	Robert Jones
1725–1730	Closing Remarks	Peter Black / Simon Tanguay

Saturday, November 1, 2025

0800–0845	B2B Breakfast Symposium	
	Innovative Technologies Transforming Bladder Cancer Care	Chair/Moderator: Peter Black Speakers: Kilian Gust, Gautier Marcq (France), Sarah Psutka (USA)

The 45th Congress of the Société Internationale d'Urologie has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®). Watch this session live and claim up to **8.0 ECMEC® credits**.

HER2-Targeted Antibody- Drug Conjugates in Metastatic Bladder Cancer: *A New Era of Precision Oncology*

B2B-02

Friday, October 31 • 12:00–12:45 GMT

Sidlaw Auditorium, L3, EICC

Chair



Karima Oualla, MD, MSc
Department of Medical Oncology, Hassan II
University Hospital, Fez, Morocco

Speakers



Viktor Grünwald, MD, PhD
Urology and Medical Oncology
Clinics, Interdisciplinary Genitourinary
Oncology, University Hospital Essen,
Essen, Germany



Kilian Gust, MD, PhD
Department of Urology, Comprehensive
Cancer Center, Medical University of
Vienna, Vienna, Austria



Daniele Raggi, MD
Genitourinary Oncology, The Royal
Marsden NHS Foundation Trust,
London, United Kingdom

This session will be transmitted live via the SIU Congress platform. **SIU @U**



This symposium is supported by B2B Presenting Sponsor Daiichi-Sankyo | AstraZeneca.

#B2BGUCancersTriad #SIU2025Edinburgh #SIUatU



October 14-17, 2026 Abu Dhabi

Join us for SIU-EUS 2026

The 46th Congress of the Société Internationale d'Urologie, presented in partnership with the Emirates Urological Society.

This unique collaboration will bring together global and regional expertise for an unforgettable programme of science, innovation, and networking.


Innovative Technologies Transforming Bladder Cancer Care

B2B-06

Saturday, November 1

08:00–08:45 GMT

Sidlaw Auditorium, L3, EICC



Chair



Peter C. Black, MD, FRCSC

Department of Urologic Sciences, University of
British Columbia, Vancouver, Canada

Speakers



Kilian Gust, MD, FEBU

Department of Urology, Comprehensive
Cancer Center, Medical University of
Vienna, Vienna, Austria



Gautier Marcq, MD, PhD

Department of Urology, Claude Huriez
Hospital, CHU Lille, Lille, France



Sarah Psutka, MD, MSc

Fred Hutchinson Cancer Center, Department
of Urology, University of Washington School
of Medicine, Seattle, WA, United States

This session will be transmitted live via the SIU Congress platform. **SIU @U**



This symposium is supported by B2B Presenting Sponsor Johnson & Johnson.

#B2BGUCancersTriad #SIU2025Edinburgh #SIUatU



Enjoy the latest content in the SIU Academy Collection: SIU 2024 Congress, Prostate Unlimited, eGrand Rounds, and other resources



Mauro Gacci
Italy – Chair,
Office of Education



Philippe Spiess
United States – Chair,
Consensus and Education

Each year, new and valuable content is added to the SIU Academy library, accessible on the user-friendly platform designed to enhance and improve SIU members' continuing medical education.





SIU Webinars



2024 Prostate Unlimited

This educational programme was supported by Astellas Pharma Inc., Boston Scientific, Karl Storz, Kerry Medical, Olympus, Pierre Fabre Medicament, Takeda Pharmaceuticals, Teleflex.

Insight: Interactive Knowledge Sharing with Experts

This educational programme was supported by Astellas Pharma Inc.

Webinar 360 Series



Global Perspectives

A Global Perspective on Prostate Cancer Management: A Focus on Diagnosis and Surgical Management

eGrand Rounds



Updates in

- Stone Management – including the latest edition from February 2025!
- Urothelial Cancer Management
- BPH Management

These educational programmes were supported by SIU Corporate Sponsor Karl Storz.

Urotrainer Hands-On Training Programme




Masterclass in Minimally Invasive Partial Nephrectomy and Radical Prostatectomy

The SIU is happy to announce a partnership with Urotrainer, endorsing their premier hands-on training programmes in laparoscopic partial nephrectomy and radical prostatectomy.

Residents' Corner

Back-to-Basics



Back-to-Basics

- Open Kidney Transplantation: Surgical Technique
- Diagnosis and Treatment of Erectile Dysfunction

Back-to-Basics: Know Your Instruments

- Robotic Instrumentation
- Retractors in Urology
- Prostate and Renal Biopsy Material
- Surgical Preparation for the Operating Theatre



Access all these great resources via your mobile device or computer

SIU Academy is fully mobile-responsive and accessible.

VISIT

siu-urology.org/academy/access-siu-academy



ICUD Publications

Consultations are an important collaborative initiative between the SIU and the International Consultation on Urological Diseases (ICUD). These joint Consultations involve numerous international experts grouped into working committees that focus on specific aspects of the Consultation topic. Their conclusions are presented during the SIU Congress and later published in a comprehensive volume that becomes a valuable international reference on the topic.



BEST OF 2024: TOP 5 SESSIONS

Revisit the best of 2024 and watch these high-yield favourites on SIU Academy

- 1 eGrand Rounds—Update in BPH Management (May 15, 2024)**
This educational programme was supported by SIU Corporate Sponsor Karl Storz.

- 2 Urotrainer—Masterclass: Minimally Invasive Partial Nephrectomy**

- 3 SIU 2024 Webcast—Luncheon Symposium: Innovations in BPH Treatment: From Clinical Data to Patient Care**
This educational programme was supported by SIU Corporate Sponsor Olympus.

- 4 eGrand Rounds—Update in Stone Management**
This educational programme was supported by SIU Corporate Sponsor Karl Storz.

- 5 eGrand Rounds: Update in BPH Management (December 6, 2023)**
This educational programme was supported by SIU Corporate Sponsor Karl Storz.



UPCOMING PUBLICATION



Stavros Gravas
Cyprus
Co-Editor



Dean Elterman
Canada
Co-Editor



Andrea Tubaro
Italy
Co-Editor

SIU-ICUD Individualized Management of Male LUTS

The SIU will host committee chairs from the SIU-ICUD Consultation on Individualized Management of Male LUTS to present their recommendations on Saturday, November 1, 11:15-12:45, during the SIU's 45th Congress in Edinburgh—watch this session live in Fintry, L3, at the EICC or online on *SIU@U*. Led by Co-Editors, **Stavros Gravas**, **Dean Elterman**,

and **Andrea Tubaro**, this Consultation will provide a comprehensive, evidence-based, and practical approach to managing individual patients with LUTS in daily clinical practice.

Accessible to SIU members and Academy subscribers, this important document will be available online at the end of 2025.

Chapters and Chairs

Lower Urinary Tract Symptoms in Men

Karel Everaert, Belgium
Philip van Kerrebroeck, Netherlands

Patient Assessment

Marcus Drake, United Kingdom

Lifestyle Intervention and Pharmacological Treatments

Andrea Tubaro, Italy

Invasive Surgical Treatments

Peter Gilling, New Zealand
Henry Woo, Australia

Minimally Invasive Treatments

Bradley Gill, United States
Kevin Zorn, Canada

Predictive Models for Patient Outcome and Success Criteria

Stavros Gravas, Cyprus

Managing Patients with Complications and Persistent Symptoms

Enrico Finazzi Agrò, Italy



Host your event on an international stage!

Submit your event to be considered for SIU endorsement.

Visit the SIU website, look under the **eLearning** tab, and select **Submit an Event** for more information.

OAB & BPO:

From Advanced Diagnosis to Personalized Management

SS-03

Saturday, November 1 • 10:45–11:15 GMT

Sidlaw Auditorium, L3, EICC

Chair



Stavros Gravas, MD, PhD, FEBU
Medical School, University of Cyprus, Nicosia, Cyprus

Speakers



Cosimo De Nunzio, MD, PhD
Department of Urology, Sant'Andrea Hospital,
University La Sapienza, Rome, Italy



Dean Elterman, MD MSc FRCSC
Division of Urology, Toronto Western Hospital, University
Health Network, University of Toronto, Toronto, Canada

This session will be transmitted live via the SIU Congress platform. SIU @U



Open Access Journal

The *Société Internationale d'Urologie Journal* (SIUJ) is an international, peer-reviewed, open access journal that covers all aspects of urology and related fields. The Journal is owned by the SIU and is published bimonthly online by MDPI (since Volume 5, Issue 1, 2024).

Open Access

Free for readers and authors (diamond open access).

Rapid Publication

In 2024, most authors received a first decision and peer reviewer feedback less than 60 days after submission, and time from acceptance to publication was 21.1 days.

Recognition of Reviewers

Reviewer names are published annually in the Journal, reviewers can choose to add their names to reviews, and they are eligible for a variety of benefits through the publisher.

EDITORIAL BOARD



Peter C. Black
Canada
Editor-in-Chief



Philippe E. Spiess
United States
Deputy Editor

ASSOCIATE EDITORS



Lysanne Campeau
Canada



Sanjay Sinha
India




Henry Woo
Australia

SIUJ: On the Horizon–Indexing

Through the rigorous work of its editorial board and the high-quality submissions of many authors from around the globe, the *SIUJ* continues to carve a space in the world of urology journals. The Journal is already indexed in the Directory of Open Access Journals (DOAJ) and EBSCO, and is listed as adhering to the Recommendations of the International Committee of Medical Journal Editors with respect to ethical standards in scholarly publishing. Now, a dedicated team is ensuring that *SIUJ* meets the rigorous requirements for indexing in PubMed Central.

Accessing the Journal



Subscribe via mdpi.com/journal/siuj to receive the eTOC for each issue and stay up to date on the latest content highlights via the *SIUJ* social media channels (X @SIU_Journal & LinkedIn).

Do you want to share your work with colleagues around the world? Go to the *SIUJ* page on MDPI at the link above to submit your research for peer review.



Journal Awards

Best Paper Award

The annual *SIUJ* Best Paper Award acknowledges high quality, scientifically important work whose publication has a significant impact. This year, the evaluation committee will choose article(s) published in the Journal from July 1, 2024, to June 30, 2025, and announce the winner(s) at the SIU Congress in Edinburgh. Winners will be awarded 500 CHF in recognition of their valuable contributions.

Outstanding Reviewer Award

The *Outstanding Reviewer Award* is given annually at the SIU Congress to recognize reviewers who generously contribute their time to reviewing papers and display thoroughness, professionalism, and timeliness. Winners will be chosen from all the previous year's reviewers and will be awarded 500 CHF in recognition of their valuable contributions.

ADVANCING NMIBC MANAGEMENT

From Clinical Evidence to Daily Practice

SS-04 • Saturday, November 1, 2025 • 12:45–14:00 GMT

Sidlaw Auditorium, L3, EICC

Co-Chairs



Peter C. Black, MD, FRCS
Department of Urologic Sciences,
University of British Columbia, Vancouver, Canada



Jeremy Y. C. Teoh, MBBS, FRCSEd (Urol), FCSHK
FHKAM (Surgery), Faculty of Medicine, The Chinese
University of Hong Kong, Hong Kong

Speakers



Paolo Gontero, MD
Department of Urology,
University of Turin, Turin, Italy



**Param Mariappan, MBBS(Hons), FRCS(Urol),
PhD, FEBU, CBU(Mal)**, Edinburgh Bladder
Cancer Surgery (EBCS), The University
of Edinburgh, Western General Hospital,
Edinburgh, United Kingdom



Vikram Narayan, MD, FACS
Department of Urology, Emory
University School of Medicine,
Atlanta, GA, United States

This session will be transmitted live via the SIU Congress platform. **SIU @U**

This symposium is supported by SIU Congress Contributor Ferring Pharmaceuticals.

#SIU2025Edinburgh #SIUatU





Mihir Desai
United States
Chair, Office of Research



Ranan Dasgupta
United Kingdom
Chair, Research Committee

Driving Collaborative Applied Research in Urology

uCARE is the Société Internationale d'Urologie's official Office of Research, created in the fall of 2017. uCARE generates opportunities for clinicians to participate in clinical studies and contribute to knowledge development and translation in urology. Join a global community of urologists, patients, and organizations committed to urological research.



**There is still time to contribute
to the BPH Global Registry!**

Find out more:
siu-urology.org/ucare/bph-registry-portal

Contact us to discover how you can get involved:
eduardo.gutierrez@siu-urology.org

AN UPDATE ON THE BPH GLOBAL REGISTRY

>146
Centres submitted

>867
Patients added
to the registry

29
Centres with
IRB approval



Scholarships

SIU Training Scholarships

The SIU offers two types of training scholarships. Urologists from the developing world who have earned their MD degree in the last 10 years are eligible to apply.

First scholarship

Allows the scholar to train in an SIU-Accredited Training Centre in the candidate's geographical area

Second scholarship

Grants the visiting scholar an observational role in an SIU-Accredited Training Centre

Both programmes offer scholarships for surgeons for a 3- or 6-month period in an FSIU-recognized institute, with **US \$5,000** for a 6-month period and **US \$2,500** for a 3-month period.



SIU-PAUSA Scholarship

The SIU and the Pan-African Urological Surgeons' Association (PAUSA) have partnered to offer a training scholarship for young urologists (within 10 years of obtaining their MD license) from Africa.

This scholarship will provide young urologists with an opportunity to enhance their skills by completing training in a non-African country. Each year, SIU and PAUSA grant one **6-month scholarship of US \$5,000 to one applicant**.



The portal for scholarship applications for 2026 will open in November 2025.

Visit the SIU website or email us at central.office@siu-urology.org for full details and requirements: siu-urology.org/society/training-scholarships

SIU Scholar Snapshots



Bushra Jawaaid

Pakistan, 2023 Scholarship recipient for Hamburg University Medical Center (UKE) in Germany

"[The SIU Scholarship] is a once-in-a-lifetime opportunity, and I am very lucky that I got it. The entire experience has been great and often feels like a dream. It has added a whole new dimension to my understanding of reconstructive urology, and I am excited to dive deeper and excel in it."

"I have found my calling in reconstructive urology and will look for more opportunities to learn further and polish my knowledge and skills in it. I am excited to apply the new techniques that I have learned from the training to my practice. There is still a long way to go but my start on this journey could not have been any better."

"I am forever humbled to SIU for giving me this opportunity. It is a great initiative and should continue. It's been an inspiring journey for me. Not only a learning experience but I also got to explore Germany and witness its beauty. I highly recommend it to young urologists like me for increasing exposure and boosting your career."

Mansour Ndoeye Diao

Senegal, 2023 Scholarship recipient for Bambino Gesù Pediatric Hospital in Italy

"I learned a different way to work in a team. For example, I appreciated the consultations with other specialists (neurosurgeon, pediatric surgeon) for harmonized decisions about a patient's follow-up."

"This was a big opportunity for me to discover and perform surgical practice that I never saw in my daily activity. That was a new experience that enriched my capacity to manage a pediatric patient. And this experience allowed me to learn other procedures that I can use for improving the follow-up of my patients."



SIU Training Centres

ARGENTINA

Hospital de Clínicas José de San Martín
<http://www.hospitaldeclinicas.uba.ar/>
Programme Director: Norberto Bernardo

CHILE

Clínica Indisa
Programme Director: Octavio Castillo
dr.octaviocastillo@gmail.com

Hospital del Trabajador
<https://www.hospitaldeltrabajador.cl/>
Programme Director: Reynaldo Gómez
gomez.reynaldo@gmail.com

CHINA

The First Affiliated Hospital, Zhejiang University
<https://www.zju.edu.cn/>
Programme Director: Li-Ping Xie
xielp@zju.edu.cn

The Third Affiliated Hospital of Sun Yat-Sen University
<http://www.zssy.com.cn>
Programme Director: Xiangfu Zhou
xiangfuzhou@126.com

First Affiliated Hospital of Medical College of Xi'an Jiaotong University
<http://www.med.xjtu.edu.cn>
Programme Director: Lei Li
lilydr@163.com

COLOMBIA

Universidad CES
<https://www.ces.edu.co/>
Programme Director: Rafael Castellanos Acosta
ricastellanos@ces.edu.co

EGYPT

University of Alexandria
<http://www.med.alexu.edu.eg/>
Programme Director: Wael Sameh
alexuro@alexmed.edu.eg

GERMANY

Universitaetsklinikum Hamburg-Eppendorf
<https://www.uke.de/index.html>
Programme Director: Margit Fisch
m.fisch@uke.de

INDIA

Medanta - The Medicity, Medanta Kidney & Urology Institute
<https://www.medanta.org/kidney-hospital/>
Programme Director: Narmada Prasad Gupta
narmadagupta@gmail.com

Muljibhai Patel Urological Hospital
<http://www.mpuh.org/>
Programme Director: Ajay Gangoli
ajay.gangoli@mpuh.org

Rajiv Gandhi Cancer Institute and Research Centre
<https://www.rgcirc.org/>
Programme Director: Sudhir Rawal
info@rgcirc.org

UROKUL Pune / Kulkarni UroSurgery Institute Pvt Ltd
<https://strictureurethra.in/>
Programme Directors: Sanjay Kulkarni and Pankaj Joshi
urokul22@gmail.com / drpankajmjoshi@gmail.com

ITALY

Bambino Gesù Pediatric Hospital
<https://www.ospedalebambinogesu.it/home>
Programme Directors: Giovanni Mossiello and Massimiliano Silveri
giovanni.mosiello@opbg.net / massimiliano.silveri@opbg.net

KENYA

East Africa Kidney Institute
<https://eaki.uonbi.ac.ke/>
Programme Director: Peter Mungai Ngugi
eaki@uonbi.ac.ke

Agha Khan University Hospital
<https://hospitals.aku.edu/nairobi/Pages/default.aspx>
Programme Director: Ahmed A. Yousef

NIGERIA

PIUTA Ibadan Center
<https://eaki.uonbi.ac.ke/>
Programme Director: Oluwabunmi Olapade-Olaopa
Info.piutaibadan@yahoo.com

PAKISTAN

Pakistan Kidney Center
<http://www.pkc.com.pk/>
Programme Director: Aasem Masood Chaudry
info@pkc.com.pk

RUSSIA

Urology Clinic of Moscow State University of Medicine and Dentistry

<https://en.msmsu.ru/>

Programme Director: Dmitry Pushkar

Pushkarmd@mail.ru

SOUTH AFRICA

University of Cape Town

<http://www.uct.ac.za/>

Programme Director: John Lazarus

j.lazarus@uct.ac.za

University of Stellenbosch & Tygerberg Hospital

<http://www.sun.ac.za/english>

Programme Director: André van der Merwe

arvdm@sun.ac.za

Steve Biko Academic Hospital, University of Pretoria

<https://sbah.org.za/>

Programme Director: Kgomotso Mathabe

kgomotsomathabe@gmail.com

TANZANIA

Institute of Urology at KCMC

<https://www.kcmc.ac.tz/>

Programme Director: Kien Alfred Mteta

akamteta@hotmail.com

TUNISIA

University Sahloul Hospital

Programme Director: Wissem Hamida

hmidawissem@gmail.com



ASM

USANZ ANZUNS

MELBOURNE 2026

28 FEB – 3 MAR







**Early Bird
Registration
NOW OPEN**

ASM.USANZ.ORG.AU



UROLOGICAL SOCIETY
OF AUSTRALIA
AND NEW ZEALAND



ANZUNS
Australia and New Zealand
Urological Nurses Society Ltd

#USANZ26



SAVE THE DATE
12-14 June
2026



FUS
5TH USANZ
Functional
Urology
Symposium
&
PPCS
20TH ANNUAL MEETING
Pan-Pacific
Continence
Society

12-14 JUNE 2026
Hyatt Regency, Sydney
✉ events@usanz.org.au

USANZ.ORG.AU/EVENT/FUS-PPCS-2026









#FUSPPCS26

urologynews

The free bimonthly UK magazine for
urologists and related urology professionals




"Urology News is a must-read for everyone involved in the
field of urology"

Jay Khastgir, Editor, Urology News



Scan the QR code to register for your free copy
www.urologynews.uk.com/register



 /UrologyNews

 /company/urology-news

 @Uro_News

SPONSOR ACKNOWLEDGEMENTS

The SIU extends its deepest gratitude to the following sponsors:

CORPORATE SPONSORS



PRESENTING SPONSORS



CONGRESS CONTRIBUTORS



SOCIETY CONTRIBUTORS





siu-urology.org